Creative Biolabs provides phage display screening for apoptosis and senescence targets with cell-state selection, multi-marker assays, and toxicity controls.
A candidate that binds a tumor cell is not automatically a candidate that induces apoptosis or senescence. It may simply recognize a highly expressed surface feature, alter proliferation without changing cell state, or reduce cell number through nonspecific toxicity. Creative Biolabs designs Functional Phage Display Screening programs so these outcomes are separated early, allowing you to distinguish state-selective binders from genuine phenotype-modulating candidates.
We can support projects that begin with a known target or with a measurable tumor-cell state. Depending on the objective, selection may compare target-positive and target-negative cells, baseline and induced states, resistant and responsive populations, or another biologically matched pair. After enrichment, candidates are tested using time-resolved and multi-marker assays rather than a single staining endpoint. This is especially important because apoptosis, transient cytostasis, quiescence, stress responses, and senescence can all reduce apparent proliferation while representing different biology.
The output can therefore be tailored to what your program actually needs: a cell-state-selective ligand, a candidate that changes apoptosis, a candidate associated with durable growth arrest, or a target hypothesis for later deconvolution. We keep binding, phenotype, and mechanism as separate evidence levels so useful binders are not discarded for lacking a function that was never required, and functional hits are not overinterpreted before target or pathway evidence is available.
| Project Goal | What Success Looks Like | Key Confirmation |
|---|---|---|
| State-selective binder discovery | Preferential binding to a defined tumor state or target-positive population. | Matched positive/negative cell binding and non-phage retesting. |
| Apoptosis-modulating candidate discovery | A reproducible apoptosis-consistent response beyond general cell loss. | Annexin/caspase or mitochondrial evidence interpreted with viability and time course. |
| Senescence-associated modulation | Persistent proliferation arrest with a complementary senescence marker profile. | SA-beta-gal or related markers plus durable arrest, cell-cycle/proliferation data, and context-appropriate markers. |
| Phenotype-first target discovery | A reproducible cell-state change without a predefined molecular target. | Target deconvolution and pathway/mechanism work after the phenotype is confirmed. |
This separation is important for both scientific interpretation and candidate value. A state-selective binder with no functional activity may still be a useful targeting reagent, research probe, or starting point for target identification. Conversely, a candidate that changes cell state in both target-positive and target-negative cells may be biologically active but not target selective. We define these acceptable endpoints before the screen rather than changing the success criteria after data are generated.
Tumor cultures are heterogeneous even before a candidate is added. Cycling, stressed, dying, quiescent, and differentiating subpopulations can coexist, and induction protocols can change cell size, membrane composition, or surface antigen density. For that reason, we favor matched comparisons such as genetically related target-positive/negative cells, baseline versus induced states, or tumor versus a biologically meaningful non-target population rather than a generic cancer/non-cancer contrast.
Time is another critical variable. Early caspase activation followed by membrane changes supports a different interpretation from late cell loss after prolonged exposure. Similarly, transient slowing of proliferation is not equivalent to durable senescence. We select time points according to the expected biology and, when appropriate, use washout or recovery experiments to ask whether a growth-arrest phenotype persists after the candidate is removed.
| Observed Change | Supporting Evidence | Common Alternative Explanation |
|---|---|---|
| Apoptosis-like response | Annexin V/PI pattern plus caspase, mitochondrial, or another pathway-consistent readout. | General toxicity, membrane damage, or late secondary death. |
| Reduced proliferation | EdU or cell-cycle change interpreted with viable cell number. | Cell loss, quiescence, nutrient stress, or assay timing. |
| Senescence-like state | Persistent arrest plus SA-beta-gal and additional molecular/morphological markers as appropriate. | Transient cytostasis, stress, or reversible arrest. |
| State-selective phage enrichment | Matched positive/negative cell binding and independent candidate retest. | Cell-number, size, membrane, or nonspecific surface differences. |
Set the intended endpoint, minimum evidence for advancement, matched positive and negative populations, relevant induction conditions, time points, and controls.
Enrich on the desired target or cell state while depleting binders to matched negative cells, related backgrounds, tags, carriers, or other non-informative materials.
Use sequencing to identify recurring families and retain round-level context, then reconfirm individual clones for state- or target-dependent binding.
Test prioritized candidates in time-resolved functional assays and retest decisive hits in the intended non-phage format to separate intrinsic activity from phage-context effects.
After the phenotype is reproducible, add target deconvolution, pathway perturbation, rescue, or other experiments that directly test the proposed mechanism.
We design project-specific marker combinations rather than relying on a single endpoint. For apoptosis-focused projects, complementary readouts can include phosphatidylserine exposure, caspase activation, mitochondrial changes, membrane integrity, viable cell number, and time course. For senescence-associated phenotypes, persistent growth arrest is interpreted together with SA-beta-gal or other context-appropriate molecular, morphological, or cell-cycle markers. Mechanistic studies are added only after the phenotype is reproducible and when they are expected to influence candidate prioritization.
Cell model and target or phenotype status
Positive and negative states or induction conditions
Library format, time points, and reference controls
Functional marker panel
Downstream mechanism question
Any existing assay constraints or preferred handoff point
Enriched phage pools and sequence-defined clones
State-selective binding comparisons
Apoptosis and viability datasets
Proliferation and cell-cycle data
Senescence-associated marker panels
Non-phage confirmation and prioritized candidates
You do not need to have every parameter finalized before contacting us. Start with the information you already have, and we can help define the remaining screening and validation design. If the molecular target is unknown, we can also plan target deconvolution early so candidate material, control cells, and follow-up assays are aligned from the start.
If you are planning an apoptosis, senescence, or tumor cell-state screening project, share your cell model, positive and negative states, target status, library format, marker panel, time points, and downstream mechanism question with us. Creative Biolabs can help you design a research-use workflow that keeps binding, toxicity, apoptosis, senescence, and target identity clearly separated.
Contact Our Experts
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
